| RIP1 Inhibitory Compounds and Methods for Making and Using the Same |
2023-6-14 |
2023-10-12 |
|
| Rip1k inhibitors |
2023-4-26 |
2023-8-24 |
|
| Tricyclic irak inhibitors |
2023-3-30 |
2023-10-05 |
|
| Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
2023-3-22 |
2023-9-28 |
|
| Rip1k inhibitors |
2023-1-13 |
2023-7-20 |
|
| Heterocyclic rip1 inhibitory compounds |
2022-12-16 |
2023-5-11 |
|
| Crystalline forms of a ripk1 inhibitor |
2022-12-07 |
2023-6-22 |
|
| Rip1 inhibitory compounds and methods for making and using the same |
2022-12-06 |
2023-10-05 |
|
| Rip1 inhibitory compounds and methods for making and using the same |
2022-11-30 |
2023-2-14 |
|
| 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
2022-11-16 |
2023-3-30 |
|
| Amide compounds and method for making and using |
2022-11-09 |
2023-4-13 |
|
| Oxazole derivative for use as irak inhibitor and method for preparing the same |
2022-11-01 |
2023-1-24 |
|
| Kinase inhibitor and methods for making and using the same |
2022-10-26 |
2023-1-24 |
|
| TGF-ß INHIBITORS |
2022-10-07 |
2023-4-20 |
|
| METHOD FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH COVID-19 |
2022-10-04 |
2022-11-30 |
|
| Nrf2 activating compounds and uses thereof |
2022-9-08 |
2022-11-22 |
|
| Method for treatment of an excessive immunological response to an infection by … |
2022-8-29 |
2023-7-16 |
|
| Irak inhibitor for treating cytokine release-related conditions associated with … |
2022-8-29 |
2023-7-16 |
|
| Pyrazole compounds, formulations thereof, and a method for using the compounds … |
2022-5-18 |
2022-9-29 |
|
| Pyrazole compounds and methods for making and using the compounds |
2022-5-18 |
2022-9-15 |
|
| Heterocyclic rip1 kinase inhibitors |
2022-3-10 |
2022-9-15 |
|
| Benzazole compounds and methods for making and using the compounds |
2022-3-07 |
2022-6-16 |
|
| Method to block or ameliorate cytokine release syndrome |
2022-3-07 |
2022-4-08 |
|
| RIP1 INHIBITOR COMPOUNDS AND METHODS FOR PREPARING AND USING THEM |
2022-3-04 |
2022-8-31 |
|
| Method for treating a disease or condition using a pyrazole compound or … |
2022-3-02 |
2022-9-15 |
|
| Compounds and method for treating cytokine release syndrome |
2022-2-04 |
2022-8-11 |
|
| Compounds and method for treating autoimmune diseases |
2021-12-10 |
2022-7-14 |
|
| Methods of treating or preventing autoimmune diseases with 2,4- … |
2021-11-19 |
2022-3-10 |
|
| Compositions and methods for inhibition of the jak pathway |
2021-11-02 |
2022-3-31 |
|
| Direct ampk activators |
2021-10-13 |
2022-3-31 |
|
| Compositions and methods for inhibition of the jak pathway |
2021-10-05 |
2022-1-27 |
|
| Tyrosine kinase inhibitors |
2021-9-10 |
2021-12-09 |
|
| Acvr2a-specific antibody and method of use thereof |
2021-8-04 |
2021-12-09 |
|
| Providing responses to queries of transcripts using multiple indexes |
2021-6-25 |
2022-12-29 |
|
| Axl inhibitors for use in combination therapy for preventing, treating or … |
2021-6-18 |
2021-12-09 |
|
| TGF-ß INHIBITORS |
2021-5-19 |
2021-9-09 |
|
| Method for treatment of covid-19-associated conditions |
2021-5-18 |
2021-9-16 |
|
| 2,4-pyrimidinediamine compounds and their uses |
2021-5-03 |
2021-9-02 |
|
| Rip1 inhibitory compounds and methods for making and using the same |
2021-3-23 |
2021-7-15 |
|
| Tyrosine kinase inhibitors |
2020-11-25 |
2021-3-18 |
|
| RIP1 INHIBITOR HETEROCYCLIC COMPOUNDS |
2020-11-06 |
2022-2-09 |
|
| Nrf2 Activating Compounds and Uses Thereof |
2020-10-20 |
2021-3-18 |
|
| RIP1 INHIBITOR COMPOUNDS AND METHODS FOR MANUFACTURING AND USING THE SAME |
2020-9-07 |
2022-1-19 |
|
| Method of blocking or ameliorating cytokine release syndrome |
2020-8-13 |
2023-11-01 |
2023-11-01 |
| Prodrugs of Nrf2 Activating Compounds and Uses Thereof |
2020-8-12 |
2020-11-26 |
|
| Antigen binding molecules to tigit |
2020-7-10 |
2020-10-29 |
|
| Prodrugs of 2,4-pyrimidinediamine compounds and their use |
2020-6-04 |
2020-6-25 |
|
| Method of preventing and treating thrombosis |
2020-5-29 |
2020-12-03 |
|
| Fumarate analogs and uses thereof in treatment of autoimmune disease or … |
2020-3-25 |
2020-7-30 |
|
| Compositions and methods for inhibition of the jak pathway |
2020-1-03 |
2020-7-09 |
|
| Method and composition embodiments for treating acute myeloid leukemia |
2019-10-31 |
2020-5-07 |
|
| 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use |
2019-7-22 |
2019-11-14 |
|
| Ampk-activating heterocyclic compounds and methods for using the same |
2019-6-25 |
2020-1-16 |
|
| Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses |
2019-6-12 |
2020-1-16 |
|
| Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl) … |
2019-5-20 |
2022-5-26 |
2022-5-26 |
| Compositions and methods for inhibition of the JAK pathway |
2019-5-06 |
2023-6-06 |
2023-6-06 |
| TGF-beta inhibitors |
2019-3-21 |
2022-6-07 |
2022-6-07 |
| NEW PHARMACEUTICAL FORMS OF (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL |
2019-2-06 |
2021-1-27 |
|
| PHARMACEUTICAL PROCESS AND INTERMEDIATE |
2018-12-04 |
2020-5-29 |
|
| GDF-8 inhibitor |
2018-11-02 |
2019-3-28 |
|
| 2.4 SUBSTITUTED PYRIMIDINDIAMINES FOR USE IN THE DISC WOLF |
2018-9-06 |
2019-12-11 |
|
| Compositions and methods for inhibition of the JAK pathway |
2018-8-13 |
2018-8-30 |
|
| Wet granulation using a water sequestering agent |
2018-7-20 |
2018-9-21 |
|
| Methods for inhibiting allograft rejection |
2018-4-24 |
2018-8-16 |
|
| Method of treating vitiligo |
2018-3-29 |
2018-7-26 |
|
| Protein kinase C inhibitors and uses thereof |
2018-3-12 |
2020-10-06 |
2020-10-06 |
| Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo … |
2017-11-09 |
2018-3-08 |
|
| Topical formulation for administering a compound |
2017-9-08 |
2018-3-01 |
|
| Tetrazolones as a carboxylic acid bioisosteres |
2017-6-08 |
2019-10-22 |
2019-10-22 |
| Protein Kinase C Inhibitors and Uses Thereof |
2017-5-05 |
2018-2-01 |
|
| Carboxamide, sulfonamide and amine compounds for metabolic disorders |
2017-4-27 |
2019-3-21 |
2019-3-21 |
| Pyrimidine-2-amine compounds and their use as JAK kinase inhibitors |
2017-3-13 |
2018-1-10 |
|
| USE OF 2,4-PYRIMIDINODIAMINES FOR THE TREATMENT OF ATHLETICOSIS |
2017-1-18 |
2017-7-12 |
|
| Substituted triazoles useful as Axl inhibitors |
2016-11-17 |
2016-12-08 |
|
| Protein kinase C inhibitors and uses thereof |
2016-9-09 |
2017-8-15 |
2017-8-15 |
| A combination for immune mediated cancer treatment |
2016-6-29 |
2017-1-12 |
|
| Substituted triazoles useful as axl inhibitors |
2016-5-05 |
2016-8-25 |
|
| Pyrazole compounds and method for making and using the compounds |
2016-4-22 |
2022-6-28 |
|
| Methods of treating ibrutinib-resistant disease |
2016-4-18 |
2016-10-27 |
|
| NUCLEAR SALT COMPOSITION OF N4- (2,2-DIMETHYL-4 - [(DYHDRONE PHOSPHONOXY) … |
2016-4-12 |
2017-4-26 |
|
| Procédé de blocage ou d'amélioration du syndrome de libération des cytokines |
2020-8-13 |
2023-11-01 |
2023-11-01 |
| Verfahren zur blockierung oder linderung des zytokinfreisetzungssyndroms |
2020-8-13 |
2023-11-01 |
2023-11-01 |